Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDM
CUSIPN/A
Phone510-265-9000
Debt
Debt-to-Equity Ratio-1.04
Current Ratio1.22
Quick Ratio1.22
Price-To-Earnings
Trailing P/E Ratio-1.99
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$14.47 million
Price / Sales1.50
Cash FlowN/A
Price / CashN/A
Book Value($0.83) per share
Price / Book-1.72
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-10,700,000.00
Net Margins-244.15%
Return on EquityN/A
Return on Assets-240.23%
Miscellaneous
Employees23
Outstanding Shares15,200,000
Market Cap$19.76 million
Aradigm (NASDAQ:ARDM) Frequently Asked Questions
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) posted its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.03. The firm had revenue of $0.26 million for the quarter. View Aradigm's Earnings History.
When is Aradigm's next earnings date?
What price target have analysts set for ARDM?
1 analysts have issued 1 year target prices for Aradigm's shares. Their forecasts range from $10.00 to $10.00. On average, they expect Aradigm's stock price to reach $10.00 in the next year. This suggests a possible upside of 599.3% from the stock's current price. View Analyst Price Targets for Aradigm.
What is the consensus analysts' recommendation for Aradigm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aradigm in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aradigm.
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include Soleno Therapeutics (SLNO), Stereotaxis (STXS), Digirad (DRAD), Dynatronics (DYNT), Nexeon Medsystems (NXNND), Nexeon Medsystems (NXNN), ENDRA Life Sciences (NDRA), Non-Invasive Monitoring Systems (NIMU), Precision Optics (PEYE), Vaso (VASO), CHF Solutions (CHFS), Fc Global Realty (FCRE), Escalon Medical (ESMC), Trimedyne (TMED) and Guided Therapeutics (GTHP).
Who are Aradigm's key executives?
Aradigm's management team includes the folowing people:
- Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 78)
- Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 61)
- Lisa Thomas, Corp. Controller
- Dr. David Cipolla Ph.D., VP of Preclinical R&D
Has Aradigm been receiving favorable news coverage?
Media headlines about ARDM stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Aradigm earned a media and rumor sentiment score of 0.15 on Accern's scale. They also gave media headlines about the company an impact score of 45.06 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Aradigm.
How do I buy shares of Aradigm?
Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aradigm's stock price today?
One share of ARDM stock can currently be purchased for approximately $1.43.
How big of a company is Aradigm?
Aradigm has a market capitalization of $19.76 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Aradigm employs 23 workers across the globe.
How can I contact Aradigm?
Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected]
MarketBeat Community Rating for Aradigm (NASDAQ ARDM)
MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
